Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance

Abstract

Background The majority of adverse drug reactions (ADRs) reported in the summary of product characteristics (SPCs) are based on pivotal clinical trials, performed under controlled conditions and with selected patients. Objectives (1) to observe ADRs in the real-world setting and to evaluate if the supervision of the pharmacist impacts on the management of ADRs and on the satisfaction of patients; (2) to sensitise health professionals and patients on the need to increase the reporting of ADRs, in compliance with Pharmacovigilance. Setting CRO Aviano, Italian National Cancer Institute. Method From February 2013 to April 2015, we conducted an observational study enrolling 154 patients (≥ 18 years) undergoing treatment with at least one of ten targeted-therapies included in the study. Main outcome ADR reporting in the real-world setting. Patient satisfaction with clinical pharmacist support. Results Reported ADRs in the real setting do not always correspond with data described in the respective SPCs. Unknown ADRs were also identified such as hyperglycaemia with lenalidomide and sorafenib; and hypomagnesaemia with bevacizumab. We also observed a 124.3% increase in spontaneous reports. Conclusion This study shows the high value of active pharmacovigilance programs, and our results might be a starting point for developing a randomised trial which should aim to demonstrate the impact of the pharmacist on improving patient’s adherence and in measuring the difference in ADRs reports in the different arms followed or not by the pharmacist.Electronic supplementary materialThe online version of this article (10.1007/s11096-018-0653-5) contains supplementary material, which is available to authorized users.

Interventions to improve adverse drug reaction reporting: A scoping review

“…Out of the 90 studies, 16 were from France; eight from Italy; seven from the United States and Spain; six from the United Kingdom and Portugal; four from Iran and India; three from China, Sweden, and Mexico; two from Brazil, Denmark, Israel, Korea, the Netherlands, Switzerland, and the United Arab Emirates; and one each from Chile, Germany, Morocco, Nigeria, Saudi Arabia, South Africa, and Thailand. The interventions were designed as before‐after in 50 of the studies, non‐comparative in 17 studies, randomized controlled trial (RCT) and cluster RCT in nine studies, and other in 14 studies. In addition, most of the studies had been developed on HCPs, particularly physicians.…”

Benzbromarone in the treatment of gout

“…Despite its safety being demonstrated in clinical trials and meta-analyses, hepatotoxicity reports raised concerns about benzbromarone and led to its withdrawal from the market. Clinical trials have a low sensitivity for detecting rare adverse events, and thus post marketing surveillance-pharmacovigilance-is necessary [53]. Some authors have questioned the lack of convincing evidence for this product's withdrawal, attributing it to a fear of lawsuits against the pharmaceutical company [10].…”

Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP)

“…Similarly, the project “FarmaREL” produced a significant increase of spontaneous AEs reporting among hematology specialists [ 32 ]. Finally, an observational study conducted by an Italian National Cancer Institute confirmed the essential role of pro-active pharmacovigilance in increasing spontaneous reporting of AEs associated with anticancer targeted-therapies [ 33 ].…”